William Blair & Company
BIVV

William Blair & Company’s Bioverativ Inc. Common Stock BIVV Stock Holding History

William Blair & Company’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-11,033
Closed -$664K – 1583
2017
Q2 		$664K Buy
11,033
+5,434
+97% +$309K 0.01% 881
2017
Q1 		$294K Buy
+5,599
New +$276K ﹤0.01% 1085

Other funds holding BIVV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

William Blair & Company's BIVV Position: Q3 2017 in Review

William Blair & Company sold out of Bioverativ Inc. Common Stock (BIVV) in Q3 2017, closing a stake of 11,033 shares — an estimated $664K sold.

William Blair & Company first reported a position in BIVV in Q1 2017 and held it in 2 quarters. The position peaked at $664K in Q2 2017. 446 funds tracked by Wall St. Rank hold BIVV as of Q3 2017.

  • William Blair & Company reported no remaining Bioverativ Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • William Blair & Company sold 11,033 Bioverativ Inc. Common Stock shares in Q3 2017, an estimated $664K.
  • William Blair & Company first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 2 quarters.
  • William Blair & Company's Bioverativ Inc. Common Stock position peaked at $664K in Q2 2017.
  • 446 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q3 2017.

Based on William Blair & Company's 13F filing for Q3 2017, filed 13 Nov 2017.